“Proteomics said the studies and note, all co-authored by Proteomics chief executive officer Dr Richard Lipscombe, showed a high correlation between the original PromarkerD mass spectrometry (MS) and the more recently developed PromarkerD immune-assay (IA) platforms and “proves the reliability of the PromarkerD test system”.
Article: Proteomics: ‘Studies Back PromarkerD For Kidney Disease’
